Vertex Pharmaceuticals Incorporated
Quick facts
| Founded | 1989 |
|---|
Marketed products
- Immunosuppressant Regimen
- IVA · Pulmonary/Respiratory
IVA is a CFTR potentiator that increases the open probability of the cystic fibrosis transmembrane conductance regulator protein to enhance chloride ion transport. - LUM · Gastroenterology
LUM001 is a β-catenin modulator that enhances Wnt/β-catenin signaling to promote the expansion and function of intestinal stem cells and barrier function. - LUM/IVA · Respiratory / Genetic disease
LUM/IVA is a combination of lumacaftor (a CFTR corrector) and ivacaftor (a CFTR potentiator) that work together to improve the processing and function of defective cystic fibrosis transmembrane conductance regulator (CFTR) protein. - Pegylated Interferon Alfa 2a · Immunology, Virology, Oncology
Pegylated Interferon Alfa 2a activates innate immune responses by binding to interferon-alpha receptors, enhancing antiviral and antiproliferative activity. - Ribavirin (Copegus®) · Virology/Infectious Disease
Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate pools and viral polymerase activity. - SUZ · Pulmonary/Respiratory
SUZ is a CFTR potentiator that enhances the function of cystic fibrosis transmembrane conductance regulator protein to improve chloride transport in cystic fibrosis patients. - Suzetrigine (SUZ) · Pain management / Neurology
Suzetrigine is a selective sodium channel inhibitor that reduces neuronal excitability by blocking voltage-gated sodium channels. - TEZ · Pulmonary/Genetic Disorders
TEZ (tezacaftor) is a CFTR corrector that helps misfolded cystic fibrosis transmembrane conductance regulator (CFTR) protein fold correctly and traffic to the cell surface.
Phase 3 pipeline
- CTX001 · Oncology / Hematologic Malignancies
CTX001 is a genetically modified T-cell therapy that enhances patient immune cells to recognize and destroy cancer cells expressing specific antigens. - ELX/TEZ/IVA · Respiratory / Genetic Disease
ELX/TEZ/IVA is a triple combination of CFTR modulators that work together to restore function of the cystic fibrosis transmembrane conductance regulator protein. - Exa-cel · Hematology/Rare Genetic Disorders
Exa-cel is an in vivo CRISPR gene-editing therapy that modifies the BCL11A gene to reactivate fetal hemoglobin production in patients with sickle cell disease or beta-thalassemia. - HB/APAP · Virology / Hepatology
HB/APAP is a combination therapy that pairs a hepatitis B antigen with acetaminophen to modulate immune responses against hepatitis B infection. - Placebo (matched to HB/APAP)
A placebo control matched to the active comparator HB/APAP (hydrocodone bitartrate/acetaminophen) that contains no pharmacologically active ingredients. - Placebo (matched to IVA)
Placebo is an inert control substance with no active pharmacological mechanism. - Placebo (matched to ivacaftor)
This drug has no therapeutic effect. - Placebo (matched to SUZ)
Placebo is an inert substance with no active pharmacological mechanism. - Placebo matched to VX-661/ ivacaftor · Pulmonary / Genetic Disorders
This is a placebo control arm in a clinical trial comparing VX-661 (a CFTR corrector) combined with ivacaftor (a CFTR potentiator) against placebo in cystic fibrosis patients. - TEZ/IVA · Pulmonology
TEZ/IVA is a combination of tezacaftor and ivacaftor, which work together to increase the function of the CFTR protein in the lungs. - Tezacaftor/Ivacaftor · Pulmonary/Respiratory
Tezacaftor is a CFTR corrector that helps misfolded cystic fibrosis transmembrane conductance regulator (CFTR) protein fold correctly, while ivacaftor is a CFTR potentiator that increases the channel-opening probability of CFTR at the cell surface. - VNZ/TEZ/D-IVA · Cystic Fibrosis
VNZ/TEZ/D-IVA is a triple combination therapy consisting of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, a corrector, and a potentiator. - VX-121/TEZ/D-IVA · Pulmonology
VX-121/TEZ/D-IVA is a triple combination of a cystic fibrosis transmembrane conductance regulator (CFTR) corrector (VX-121), a CFTR potentiator (tezacaftor), and a CFTR amplifier (ivacaftor). - VX-445/TEZ/IVA · Pulmonology
VX-445/TEZ/IVA is a combination of three cystic fibrosis transmembrane conductance regulator (CFTR) modulators. - VX-661/Ivacaftor · Respiratory
VX-661/Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector. - VX-661 plus ivacaftor combination · Respiratory
VX-661 is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector, and ivacaftor is a CFTR potentiator. - VX-770 · Respiratory / Genetic Disorders
VX-770 is a CFTR potentiator that increases the opening probability and duration of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel at the cell surface. - VX-809 · Cystic Fibrosis
VX-809 is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector. - VX-880 · Ophthalmology
VX-880 is a stem cell therapy that aims to restore vision in patients with advanced retinitis pigmentosa.
Phase 2 pipeline
- Ivacaftor Exposed · Respiratory
Potentiates CFTR chloride channel function - VX-147
- VX-150
- VX-152
- VX-407
- VX-440
- VX-509
- VX-548
- VX-659
- VX-661
- VX-670
- VX-765
- VX-787
- VX-950
- VX-993
Phase 1 pipeline
- 14C-VX-993
- AVN-944 capsules for oral administration
- Cethrin · Other
- telaprevir formulation A
- telaprevir Formulation B
- telaprevir Formulation C
- telaprevir Formulation D
- VCH-222
- VCH 916
- VX-118
- VX-264
- VX-272
- VX-445
- VX-522 mRNA therapy
- VX-581
- VX-634
- VX-668
- VX-708
- VX-809 & VX-770
- VX-828
- VX-840
- VX-973
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Vertex Pharmaceuticals Incorporated portfolio CI brief
- Vertex Pharmaceuticals Incorporated pipeline updates RSS
Frequently asked questions about Vertex Pharmaceuticals Incorporated
What are Vertex Pharmaceuticals Incorporated's marketed drugs?
Top marketed products include Immunosuppressant Regimen, IVA, LUM, LUM/IVA, Pegylated Interferon Alfa 2a, Ribavirin (Copegus®).
What is Vertex Pharmaceuticals Incorporated's pipeline?
Vertex Pharmaceuticals Incorporated has 19 drugs in Phase 3, 15 in Phase 2, 22 in Phase 1. Late-stage candidates include CTX001, ELX/TEZ/IVA, Exa-cel, HB/APAP.
When was Vertex Pharmaceuticals Incorporated founded?
Vertex Pharmaceuticals Incorporated was founded in 1989.
Related
- Immunosuppressant Regimen
- IVA · Pulmonary/Respiratory
- LUM · Gastroenterology
- LUM/IVA · Respiratory / Genetic disease
- Pegylated Interferon Alfa 2a · Immunology, Virology, Oncology
- Sector hub: All tracked pharma companies